Last Tuesday, on January 21st, 2014, the Swiss pharmaceutical company Roche published a press release on the first results of two Phase III studies with its glycine transporter inhibitor bitopertin (RG-1678) in patients with schizophrenia. Continue reading
The possible association of gastrointestinal bleeding and treatment with selective serotonin reuptake inhibitors (SSRIs) has long been known. SSRIs decrease the concentration of serotonin in platelets dramatically (> 80%). This leads to reduced platelet aggregation and results in increased tendency to bleed. The combination with non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or warfarin increases the risk further. Continue reading
In recent years it has become increasingly clear that in addition to other environmental factors, diet plays a significant role in the development of mental disorders. Since polyunsaturated omega-3 fatty acids (ω-3 PUFA) are “essential”, i.e. they cannot be synthesized by humans themselves, they but must be taken with food. Thus, their adequate intake with diet is of particular importance. Continue reading
Dear readers of my blog,
I wish you a happy New Year, with personal happiness, professional success and most of all good health. Realize your plans, work on the implementation of your dreams, develop your creativity, and break new ground: All this I wish you!
Psychiatry – and especially psychopharmacology – are in a very exciting process in which habits, which we have followed for years and decades, are called into question. Continue reading